Ovarian Carcinoma clinical trials

Explore recruiting ovarian carcinoma clinical trials.

Recruiting ovarian carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ovarian Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial

Italy, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

Spain, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

CHIPPI-1808: Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)

France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

EPITOME-1015-I: A phase I study to investigate the safety and tolerability of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Ovarian Carcinoma trials by city

Ovarian Carcinoma in Toronto Ovarian Carcinoma in Vancouver Ovarian Carcinoma in Montreal Ovarian Carcinoma in Calgary Ovarian Carcinoma in Edmonton Ovarian Carcinoma in Ottawa Ovarian Carcinoma in Winnipeg Ovarian Carcinoma in Quebec City Ovarian Carcinoma in Hamilton Ovarian Carcinoma in Kitchener Ovarian Carcinoma in London Ovarian Carcinoma in Halifax Ovarian Carcinoma in New York Ovarian Carcinoma in Los Angeles Ovarian Carcinoma in Chicago Ovarian Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease